Cantor Fitzgerald Reiterates Overweight on Fortress Biotech
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on Fortress Biotech (NASDAQ:FBIO).
June 20, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on Fortress Biotech, indicating a positive outlook for the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100